Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry

Journal of Mass Spectrometry

Volumn 40, Issue 3, 2005, Pages 389-399

  Liu, Zhongfa ^a   Floss, Heinz G ^b   Cassady, John M ^a   Chan, Kenneth K ^a,c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Ansamitocin P 3; Anti tumor drugs; Liquid chromatography tandem mass spectrometry; Maytansine; Metabolism

Indexed keywords

BLOOD; DECOMPOSITION; ESTERS; LIQUID CHROMATOGRAPHY; LIVING SYSTEMS STUDIES; MASS SPECTROMETRY; METABOLISM; METABOLITES; OXIDATION; TOXICITY; TUMORS;

CYTOTOXICITY; DEMETHYLATION; HUMAN LIVER MICROSOMES; MAYTANSINE;

DRUG PRODUCTS;

10 O DEMETHYLANSAMITOCIN P 3; 10O,20O DIDEMETHYLANSAMITOCIN P 3; 15 HYDROXYANSAMITOCIN P 3; 2' N DEMETHYLMAYTANSINE; 2' N FORMYL MAYTANSINE; 2' N,10 O DIDEMETHYLMAYTANSINE; 2' N,20 O DIDEMETHYLMAYTANSINE; 20 O DEMETHYLANSAMITOCIN P 3; 26 HYDROXYANSAMITOCIN P 3; ANSAMITOCIN P 3; ANTINEOPLASTIC AGENT; DEMETHYLHYDROXYANSAMITOCIN P 3; DIDEMETHYLHYDROXYANSAMITOCIN P 3; DRUG METABOLITE; MAYTANSINE; MAYTANSINOL; N,10 O DIDEMETHYLANSAMITOCIN P 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DECOMPOSITION; DEMETHYLATION; DRUG FORMULATION; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS FRAGMENTOGRAPHY; NONHUMAN; OXIDATION; PLASMA; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; MALE; MAYTANSINE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 15344347928     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.800     Document Type: Article

References (26)

1. Kupchan SM, Komoda Y, Court WA, Thomas GJ, Smith RM, Karim A, Gilmore CJ, Haltiwanger RC, Bryan RF. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J. Am. Chem. Soc. 1972; 94: 1354.
2. Kupchan SM, Komoda Y, Branfman AR, Dailey RG, Zimmerly VA. Tumor inhibitors. 96. Novel maytansinoids. structural interrelations and requirements for antileukemic activity. J. Am. Chem. Soc. 1974; 96: 3706.
3. Kupchan SM, Komoda Y, Thomas GJ, Hintz HPJ. Maytanprine and maytanbutine, new antileukemic ansa macrolides from Maytenus buchananii. J. Chem. Soc., Chem. Commun. 1972; 1065.
4. Boyd MR, Paull KD. Drug Dev. Res. 1995; 34: 91.
5. Ravry MJ, Omura GA, Birch R. Phase II evaluation of maytansine (NSC 153 858) in advanced cancer. A Southeastern Cancer Study Group trial. Am. J. Clin. Oncol. (CCT) 1985; 8: 148.
6. Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blättler WA, Chari RVJ. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. USA 1996; 93: 8618.
7. Komoda Y, Kishi T. In Anticancer Agents Based on Natural Product Models, Douros J, Cassady JM (eds). Academic Press: New York, 1980; 353-389.
8. Reider PJ, Roland DM. In The Alkaloids, Brossi A (ed.). Academic Press: New York, 1984; 71-156.
9. Smith CRJ, Powell RG. In Alkaloids, Pelletier SW (ed.). J Wiley: New York, 1984; 149.
10. Larson GM, Schaneberg BT, Sneden AT. Two New maytansinoids from Maytenus buchananii. J. Nat. Prod. 1999; 62: 361.
11. Feng SC, Tang ZJ, Yang YP, Xu RS, Zhong QX, Zhong Y. Chin. Chem. Lett. 1994; 5: 743.
12. Suwanborirux K, Chang CJ, Spjut RW, Cassady JM. Ansamitocin P-3, a maytansinoid, from Claopodium crispifolium and Anomodon attenuatus or associated actinomycetes. Experientia 1990; 46: 117.
13. Sakai K, Ichikawa T, Yamada K, Yamashita M, Tanimoto M, Hikita A, Ijuin Y, Kondo K. Antitumor principles in mosses: the first isolation and identification of maytansinoids, including a novel 15-methoxyansamitocin P-3. J. Nat. Prod. 1988; 51: 845.
14. Cassady JM, Chan KK, Floss HG, Leistner E. Recent development in the maytansine antitumor agents. Chem. Pharm. Bull. 2004; 52: 1.
15. Higashide E, Asai M, Ootsu K, Tanida S, Kozai Y, Hasegawa T, Kishi T, Sugino Y, Yoneda M. Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. Nature 1977; 270: 721.
16. Kupchan SM, Sneden AT, Branfman AR, Howie GA, Rebhun LI, McIvor WE, Wang RW, Schnaitmann TC. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J. Med. Chem. 1978; 21: 31.
17. Kawai A, Akimoto H, Kozai Y, Ootsu K, Tanida S, Hashimoto N, Nomura H. Chemical modification of ansamitocins. III. Synthesis and biological effects of 3-acyl esters of maytansinol. Chem. Pharm. Bull. 1984; 32: 3441.
18. Izawa M, Wada Y, Kasahara F, Asai M, Kishi T. Hydroxylation of ansamitocin P-3. J. Antibiot. 1981; 34: 1591.
19. Wani MC, Taylor HL, Wall ME. Plant antitumor agents: colubrinol acetate and colubrinol, antileukemia ansa macrolide from Colubrinol texensis. J. Chem. Soc., Chem. Commun. 1973; 390.
20. Sneden AT, Beemsterboer GL. Normaytansine, a new antileukemic ansa macrolide from Maytenus buchananii. J. Nat. Prod. 1980; 43: 637.
21. Izawa M, Nakahama K, Kasahara F, Asai M, Kida M, Kishi T. Demethylation of ansamitocins and related compounds. J. Antibiot. 1981; 34: 1587.
22. Suchocki JA, Sneden AT. Characterization of decomposition products of maytansine. J. Pharm. Sci., 1987; 76: 738.
23. Izawa M, Tanida S, Asai M. Ansamitocin analogs from a mutant strain of Nocardia. II. Isolation and structure. J. Antibiot. 1981; 34: 496.
24. Plattner RD, Powell RG. Tandem mass spectrometry of maytansinoids. J. Nat. Prod. 1986; 49: 475.
25. Weiss M. Metabolite residence time: influence of the first-pass effect. Br. J. Clin. Pharmacol. 1986; 22: 121.
26. Hjelmeland LM, Aronow L, Trudell JR. Intramolecular determination of primary kinetic isotope effects in hydroxylations catalyzed by cytochrome P-450. Biochem. Biophys. Res. Commun. 1977; 76: 541.